ArticleNucleic acids research2007
Optimization and characterization of tRNA-shRNA expression constructs.
Article in Nucleic acids research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Infection-sensing minigenome as a novel therapeutic approach against Ebola virus.Molecular therapy. Nucleic acids · 2025Article
- Programmable siRNA pro-drugs that activate RNAi activity in response to specific cellular RNA biomarkers.Molecular therapy. Nucleic acids · 2022Article
- Article
- Efficient Knockdown and Lack of Passenger Strand Activity by Dicer-Independent shRNAs Expressed from Pol II-Driven MicroRNA Scaffolds.Molecular therapy. Nucleic acids · 2019Article
- The Structure-To-Function Relationships of Gammaherpesvirus-Encoded Long Non-Coding RNAs and Their Contributions to Viral Pathogenesis.Non-coding RNA · 2018Review
- Expression of short hairpin RNAs using the compact architecture of retroviral microRNA genes.Nucleic acids research · 2017Article
- Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs.Molecular therapy. Nucleic acids · 2017Article
- High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.Molecular therapy. Nucleic acids · 2015Article
- Article
- Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Versatile microRNA biogenesis in animals and their viruses.RNA biology · 2014Review
- Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.Acta naturae · 2013Article
- microRNAs in parasites and parasite infection.RNA biology · 2013Review
- RNase III-independent microRNA biogenesis in mammalian cells.RNA (New York, N.Y.) · 2012Article
- Current progress and challenges in HIV gene therapy.Future virology · 2011Article
- Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants.Molecular cell · 2011Review
- Novel RNA-based strategies for therapeutic gene silencing.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- A mammalian herpesvirus uses noncanonical expression and processing mechanisms to generate viral MicroRNAs.Molecular cell · 2010Article
- Mature and functional viral miRNAs transcribed from novel RNA polymerase III promoters.RNA (New York, N.Y.) · 2010Article
- Concepts in in vivo siRNA delivery for cancer therapy.Journal of cellular physiology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Expression of short hairpin RNAs via the use of PolIII-based transcription systems has proven to be an effective mechanism for triggering RNAi in mammalian cells. The most popular promoters for this purpose are the U6 and H1 promoters since they are easily manipulated for expression of shRNAs with defined start and stop signals. Multiplexing (the use of siRNAs against multiple targets) is one strategy that is being developed by a number of laboratories for the treatment of HIV infection since it increases the likelihood of suppressing the emergence of resistant virus in applications. In this context, the development of alternative small PolIII promoters other than U6 and H1 would be useful. We describe tRNA(Lys3)-shRNA chimeric expression cassettes which produce siRNAs with comparable efficacy and strand selectivity to U6-expressed shRNAs, and show that their activity is consistent with processing by endogenous 3' tRNAse. In addition, our observations suggest general guidelines for expressing effective tRNA-shRNAs with the potential for graded response, to minimize toxicities associated with competition for components of the endogenous RNAi pathway in cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.